- Home
- SNTI vs TENX Comparison
SNTI vs TENX Comparison
Compare SNTI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNTI | TENX |
|---|---|---|
| Founded | 2016 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 56.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SNTI | TENX |
|---|---|---|
| Price | $1.18 | $13.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.00 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 4.4M | 216.0K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $150.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $4.63 |
| 52 Week High | $5.10 | $14.22 |
Technical Indicators
Market Signals| Indicator | SNTI | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 34.21 | 86.04 |
| Support Level | $1.15 | $10.40 |
| Resistance Level | $1.29 | $10.55 |
| Average True Range (ATR) | 0.23 | 0.83 |
| MACD | -0.08 | 0.30 |
| Stochastic Oscillator | 2.89 | 78.85 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.